St. John’s Wort

  • Dean Filandrinos
  • Thomas R. Yentsch
  • Katie L. Meyers
Part of the Forensic Science and Medicine book series (FSM)


St. John’s wort has demonstrated clinical efficacy for mild to moderate depression and compares favorably to other more potent or toxic antidepressants. Low side effects and potential benefits warrant its use as a first-line agent for select patients with mild to moderate depression or anxiety-related conditions. Benefits related to other reported uses such as an antimicrobial, agent to treat neuropathic pain, antiinflammatory, treatment alternative for atopic dermatitis, and antioxidant are either not well documented or evidence is encouraging but not conclusive and further study is needed. St. John’s wort has an inherently wide margin of safety when taken by itself, with most reported adverse drug reactions (ADRs) being related to skin reactions. Isolated, but more significant ADRs have been reported in relation to neurological effects, impact on thyroid function, and increased prothrombin time. Of greatest concern is the potential for interactions between St. John’s wort and mainstream pharmaceuticals through induction of cytochrome P450. Patients on concomitant treatment with drugs metabolized through this pathway should be monitored closely for altered drug effect.

Key Words

Hypericum perforatum hypericin hyperforin antidepressant anxiolytic P450 enzyme induction 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bradshaw C, Nguyen A, Surles J.∼cebradsh/stjohn.html. Date accessed: Oct 28, 1998.
  2. 2.
    United States Pharmacopeial Convention (USP), ed. Hypericum (St. John’s wort). Botanical Monograph Series. Rockville: United States Pharmacopeial Convention, 1998.Google Scholar
  3. 3.
    Barnes J, Anderson LA, Phillipson JD. St. John’s wort (Hypericum perforatum L.): areview of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol 2001;53:583–600.PubMedCrossRefGoogle Scholar
  4. 4.
    Pepping J. Alternative therapies. St. John’s wort: Hypericum perforatum. Am J Health Syst Pharm 1999;56:329–330.PubMedGoogle Scholar
  5. 5.
    Bennett DAJr, Phun L, Polk JF, Voglino SA, Zlotnik V, Raffa RB. Neuropharmacology of St. John’s Wort (Hypericum). Ann Pharmacotherapy 1998;32:1201–1208.CrossRefGoogle Scholar
  6. 6.
    Schulz V. Clinical trials with Hypericum extracts in patients with depressionresults, comparisons, conclusions for therapy with antidepressant drugs. Phytomedicinc 2002;9:469–474.Google Scholar
  7. 7.
    Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St. John’s wort for depression—an overview and meta-analysis of randomized clinical trials. BMJ 1996;313:253–258.PubMedGoogle Scholar
  8. 8.
    Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St. John’s Wort in major depression. JAMA 2001;285(15): 1978–1986.PubMedCrossRefGoogle Scholar
  9. 9.
    Davidson JRT, Gadde KM, Fairbank JA, Krishnan KRR, Califf RM, Binanay C. Effect of Hypericum perforatum (St. John’s Wort) in major depressive disorder. JAMA 2002;287(14): 1807–1814.CrossRefGoogle Scholar
  10. 10.
    Szegedi A, Konnen R, Dienel A, Kieser M. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St. John’s wort): randomized controlled double blind non-inferiority trial versus paroxetine. BMJ 2005;330:503–508.PubMedCrossRefGoogle Scholar
  11. 11.
    Singer A, Wonnemann M, Muller WE. Hyperforin, a major antidepressant constituent of St. John’s Wort, inhibits serotonin uptake by elevating free intracellular Na+. J Pharmacol Exp Ther 1999;290(3): 1363–1368.PubMedGoogle Scholar
  12. 12.
    Calapai G, Crupi A, Firenzuoli F, et al. Serotonin, norepinephrine, and dopamine involvement in the antidepressant action of Hypericum Perforatum. Pharmacopsychiatry 2001;34:45–49.PubMedCrossRefGoogle Scholar
  13. 13.
    Muller WE, Singer A, Wonnemann M, Hafner U, Rolli M, Schafer C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of Hypericum Extract. Pharmacopsychiatry 1998;31(Suppl): 16–21.PubMedGoogle Scholar
  14. 14.
    Calapai G, Crupi A, Firenzuoli F, et al. Interleukin-6 involvement in antidepressant action of Hypericum Perforatum. Pharmacopsychiatry 2001;34(Suppl l):S8–S10.PubMedCrossRefGoogle Scholar
  15. 15.
    Fiebich BL, Hollig A, Lieb K. Inhibition of substance P-induced cytokine synthesis by St. John’s Wort extracts. Pharmacopsychiatry 2001;34(Suppl 1):S26–S28.PubMedCrossRefGoogle Scholar
  16. 16.
    Kleber E, Obry T, Hippeli S, Schneider W, Elstner EF. Biochemical activities of extracts from Hypericum perforatum L. Drug Res 1999;2:106–109.Google Scholar
  17. 17.
    Raffa R. Screen of receptor and uptake-site activity of hypericin component of St. John’s wort reveals receptor binding. Life Sci 1998;62:PL265–270.PubMedCrossRefGoogle Scholar
  18. 18.
    Butterweck V, Nahrstedt A, Evans J, et al. In vitro receptor screening of pure constituents of St. John’s wort reveals novel interactions with a number of GPCRs. Psychopharmacology 2002; 162:193–202.PubMedCrossRefGoogle Scholar
  19. 19.
    Simmen U, Bobirnac I, Ullmer C, et al. Antagonist effect of pseudohypericin at CRF1 receptors. Eur J Pharmacol 2003;458:251–256.PubMedCrossRefGoogle Scholar
  20. 20.
    Jensen AG, Hansen SH, Nielsen EO. Adhyperforin as a contributor to the effect of Hypericum perforatum L. in biochemical models of antidepressant activity. Life Sci 2001;68:1593–1605.PubMedCrossRefGoogle Scholar
  21. 21.
    Kumar V, Jaiswal AK, Singh PN, Bhattacharya SK. Anxiolytic activity of Indian Hypericum perforatum Linn: an experimental study. Indian J Exp Biol 2000;38:36–41.PubMedGoogle Scholar
  22. 22.
    Taylor L, Kobak KA. An open-label trial of St. John’s Wort (Hypericum perforatum) in obsessive-compulsive disorder. J Clin Psychiatry 2000;61:575–578.PubMedCrossRefGoogle Scholar
  23. 23.
    Schulz H, Jobert M. Effects of hypericum extract on the sleep EEG in older volunteers. J Geriatr Psychiatry Neurol 1994;7(Suppl 1):S39–S43.PubMedCrossRefGoogle Scholar
  24. 24.
    Volz HP, Murck H, Kasper S, Moller HJ. St. John’s wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. Psychopharmacology 2002;164:294–300.PubMedCrossRefGoogle Scholar
  25. 25.
    Schempp CM, Pelz K, Wittmer A, Schopf E, Simon JC. Antibacterial activity of hyperforin from St. John’s wort, against multiresistant Staphylococcus aureus and gram-positive bacteria. Lancet 1999;353:2129.PubMedCrossRefGoogle Scholar
  26. 26.
    Liebes L, Mazur Y, Freeman D, et al. A method for the quantification of hypericin, an antiviral agent, in biological fluids by high-performance liquid chromatography. Anal Biochem 1991;195:77–85.PubMedCrossRefGoogle Scholar
  27. 27.
    Lavie G, Valentine F, Levin B, et al. Studies of the mechanisms of action of the antiretroviral agents hypericin and pseudohypericin. Proc Natl Acad Sci USA 1989;86:5963–5967.PubMedCrossRefGoogle Scholar
  28. 28.
    Taher MM, Lammering GM, Hershey CM, Valerie KC. Mood-enhancing antidepressant St. John’s Wort inhibits the activation of human immunodeficiency virus gene expression by ultraviolet light. Life 2002;54:357–364.PubMedGoogle Scholar
  29. 29.
    Gulick RM, McAuliffe V, Holden-Wiltse J, Crampacker C, Liebes L, Stein DS, for the AIDS Clinical Trials Group 150 and 258 Protocol Teams. Phase I studies of hypericin, the active compound in St. John’s wort, as an antiretroviral agent in HI Vinfected adults. Ann Intern Med 1999;130:510–514.PubMedGoogle Scholar
  30. 30.
    Okpanyi SN, Lidzba H, Scholl BC, Miltenburger HG. Genotoxicity of a standardized hypericum extract. Arzneimittelforschung 1990;40:851–855.PubMedGoogle Scholar
  31. 31.
    Sindrup SH, Madsen C, Bach FW, Gram LF, Jensen TS. St. John’s wort has no effect on pain in polyneuropathy. Pain 2000;91:361–365.CrossRefGoogle Scholar
  32. 32.
    Albert D, Zundorf I, Dingermann T, Muller WE, Steinhilber D, Werz O. Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem Pharmacol 2002;64:1767–1775.PubMedCrossRefGoogle Scholar
  33. 33.
    Tedeschi E, Menegazzi M, Margotto D, Suzuki H, Forstermann U, Kleinert H. Antiinflammatory actions of St. John’s Wort: inhibition of human inducible nitric-oxide synthase expression by down-regulating signal transducer and activator of transcription-α (STAT-1 α) activation. J Pharmacol Exp Ther 2003;307:254–261.PubMedCrossRefGoogle Scholar
  34. 34.
    Schempp CM, Windeck T, Hezel S, Simon JC. Topical treatment of atopic dermatitis with St. John’s wort cream—a randomized, placebo controlled, double blind half-sided comparison. Phytomedicine 2003;10(Suppl IV):31–37.PubMedCrossRefGoogle Scholar
  35. 35.
    Hunt EJ, Lester CE, Lester EA, Tackett RL. Effect of St. John’s wort on free radical production. Life Sci 2001;69:181–190.PubMedCrossRefGoogle Scholar
  36. 36.
    Stevinson C, Ernst E. A pilor study of Hypericum perforation for the treatment of premenstrual syndrome. Br J Obstet Gynaecol 2000; 107:870–876.Google Scholar
  37. 37.
    Orellana C. St. John’s Wort helps to fight bladder cancer. Lancet Oncol 2001;2:399.CrossRefGoogle Scholar
  38. 38.
    HostanskaK, Bommer S, Weber M, Krasniqi B, Sailer R. Comparison of the growthinhibitory effect of Hypericum perforatum L. extracts, differing in the concentration of phloroglucinols and flavonoids, on leukaemia cells. J Pharm Pharmacol 2003;55:973–980.CrossRefGoogle Scholar
  39. 39.
    Roscetti G, Franzese O, Comandini A, Bonmassar E. Cytotoxic activity of Hypericum perforatum L. on K562 erythroleukemic cells: differential effects between methanolic extract and hypericin. Phytother Res 2004;18:66–72.PubMedCrossRefGoogle Scholar
  40. 40.
    Kimura H, Harris MS, Sakamoto T, et al. Hypericin inhibits choroidal endothelial cell proliferation and cord formation in vitro. Curr Eye Res 1997;16:967–972.PubMedCrossRefGoogle Scholar
  41. 41.
    Staffel dt B, Kerb R, Brockmoller J, Ploch M, Roots I. Pharmacokinetics of hypericin and pseudohypericin after oral intake of Hypericum perforatum extract LI 160 in healthy volunteers. J Geriatr Psychiatry Neurol 1994;7(Suppl 1):S47–S53.PubMedCrossRefGoogle Scholar
  42. 42.
    Kerb R, Brockmoller J, Staffeldt B, Ploch M, Roots I. Single-dose and steady state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother 1996;40:2087–2193.PubMedGoogle Scholar
  43. 43.
    Schulz V. Incidence and clinical relevance of the interactions and side effects of Hypericum preparations. Phytomedicine 2001;8(2): 152–160.PubMedGoogle Scholar
  44. 44.
    Ernst E, Rand JI, Barnes J, Stevinson C. Adverse effects profile of the herbal antidepressant St. John’s wort (Hypericum perforatum L.). Eur J Clin Pharmacol 1998;54:589–594.PubMedCrossRefGoogle Scholar
  45. 45.
    Brockmoller J, Reum T, Bauer S, Kerb R, Hubner WD, Roots I. Hypericin and Pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 1997;30(Suppl):94–101.PubMedGoogle Scholar
  46. 46.
    Holme SA, Roberts DL. Erythroderma associated with St. John’s wort. Brit J Dermatol 2000;143:1097–1131.CrossRefGoogle Scholar
  47. 47.
    Sultana D, Peindl KS, Wisner KL. Rash associated with St. John’s Wort treatment in premenstrual dysphoric disorder. Arch Womens Ment Health 2000;3:99–101.CrossRefGoogle Scholar
  48. 48.
    Lane-Brown MM. Photosensitivity associated with herbal preparations of St. John’s wort (Hypericum perforatum). Med J Aust 2000; 172:302.PubMedGoogle Scholar
  49. 49.
    Schempp CM, Muller K. Single-dose and steady-state administration of Hypericum perforatum extract (St. John’s Wort) does not influence skin sensitivity to UV radiation, visible light, and solar-simulated radiation. Arch Dermatol 2001; 137:512–513.PubMedGoogle Scholar
  50. 50.
    Roberts JE, Wang RH, Tan IP, Datillo M, Chignell CF. Hypericin (active ingredient in St. John’s Wort) photooxidation of lens proteins. Abstracts of the 27th Annual Meeting of the American Society of Photobiology 1999;42S.Google Scholar
  51. 51.
    Laird RD, Webb M. Psychotic episode during use of St. John’s wort. J Herb Pharmacother 2001;l(2):81–87.CrossRefGoogle Scholar
  52. 52.
    Parker V, Wong AHC, Boon HS, Seeman MV. Adverse reactions to St. John’s Wort. Can J Psych 2001;46(l):77–79.Google Scholar
  53. 53.
    Brown TM. Acute St. John’s Wort toxicity. Am J Emerg Med 2000;18(2):231–232.PubMedCrossRefGoogle Scholar
  54. 54.
    Patel S, Robinson R, Burk M. Hypertensive crisis associated with St. John’s Wort. Am J Med 2002; 112:507–508.PubMedCrossRefGoogle Scholar
  55. 55.
    Lantz MS, Buchalter E, Giambanco V. St. John’s Wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol 1999; 12:7–10.PubMedCrossRefGoogle Scholar
  56. 56.
    Gordon JB. SSRIs and St. John’s Wort: possible toxicity? Am Fam Physician 1998;57(5):952–953.Google Scholar
  57. 57.
    Nierenberg AA, Burt T, Matthews J, Weiss AP. Mania associated with St. John’s Wort. Soc Biol Psych 1999;46:1707–1708.CrossRefGoogle Scholar
  58. 58.
    Moses EL, Mallinger AG. St. John’s Wort: three cases of possible mania induction. J Clin Psychopharmacol 2000;20(l): 115–117.PubMedCrossRefGoogle Scholar
  59. 59.
    Dean AJ. Suspected withdrawal syndrome after cessation of St. John’s wort. Ann Pharmacother 2003;37:150.PubMedCrossRefGoogle Scholar
  60. 60.
    Ferko N, Levine MAH. Evaluation of the association between St. John’s Wort and elevated thyroid-stimulating hormone. Pharmacotherapy 2001;21(12): 1574–1578.PubMedCrossRefGoogle Scholar
  61. 61.
    Bhopal JS. St. John’s Wort-induced sexual dysfunction. Can J Psych 2001;46(5):456–457.Google Scholar
  62. 62.
    Markowitz JS, DeVane CL, Boulton DW, Carson SW, Nahas Z, Risch SC. Effect of St. John’s Wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 2000;66(9): 133–139.CrossRefGoogle Scholar
  63. 63.
    Roby CA, Dryer DA, Burstein AH. St. John’s Wort: effect on CYP2D6 activity using dextromethorphan-dextrorphan ratios. J Clin Psychopharmacol 2001;21(5):530–532.PubMedCrossRefGoogle Scholar
  64. 64.
    Wenk M, Todesco L, Krahenbuhl S. Effect of St. John’s Wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol 2004;57(4):495–499.PubMedCrossRefGoogle Scholar
  65. 65.
    Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St. John’ s wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001:317–326.Google Scholar
  66. 66.
    Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH. St. John’ s Wort: effect on CYP3A4 activity. Clin Pharmacol Ther 2000;67(5):451–457.PubMedCrossRefGoogle Scholar
  67. 67.
    Peebles KA, Baker RK, Kurz EU, Schneider BJ, Kroll DJ. Catalytic inhibition of human DNA topoisomerase Ha by hypericin, a naphthodianthrone from St. John’s wort (Hypericum perforatum). Biochem Pharmacol 2001;62:1059–1070.PubMedCrossRefGoogle Scholar
  68. 68.
    Wentworth M, Agostini M, Love J, Schwabe JW, Chatterjee VKK. St. John’s wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 2000;166:R11–R16.PubMedCrossRefGoogle Scholar
  69. 69.
    Moore LB, Goodwin B, Jones SA, et al. St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 2000;97(13):7500–7502.PubMedCrossRefGoogle Scholar
  70. 70.
    Komoroski BJ, Zhang S, Cai H, et al. Induction and inhibition of cytochromes P450 by the St. John’s wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 2004;32(5):512–518.PubMedCrossRefGoogle Scholar
  71. 71.
    Wang E, Barecki-Roach M, Johnson WW. Quantitative characterization of direct Pglycoprotein inhibition by St. John’s wort constituents hypericin and hyperforin. J Pharm Pharmacol 2004;56:123–128.PubMedCrossRefGoogle Scholar
  72. 72.
    Izzo AA. Drug interactions with St. John’s Wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther 2004;42(3): 139–148.PubMedGoogle Scholar
  73. 73.
    Hennessy M, Kelleher D, Spiers JP, etal. St. John’s wort increases expression of Pglycoprotein: implications for drug interactions. Br J Clin Pharmacol 2002;53:75–82.PubMedCrossRefGoogle Scholar
  74. 74.
    Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. Drug interaction between St. John’s Wort and cyclosporine. Ann Pharmacotherapy 2000;34:1013–1016.CrossRefGoogle Scholar
  75. 75.
    Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. Acute heart transplant rejection due to Saint John’s wort. Lancet 2000;355:548–549.PubMedCrossRefGoogle Scholar
  76. 76.
    Breidenbach TH, Hoffmann MW, Becker TH, Schlitt H, Klempnauer J. Drug interaction of St. John’s wort with ciclosporin. Lancet 2000;355:1912.PubMedCrossRefGoogle Scholar
  77. 77.
    Mai I, Kruger H, Budde K, et al. Hazardous pharmacokinetic interaction of Saint John’s wort (Hypericum perforatum) with the immunosuppressant cyclosporine. Int J Clin Pharmacol Ther 2000;38(10):500–502.PubMedGoogle Scholar
  78. 78.
    Moschella C, Jaber BL. Interaction between cyclosporine and Hypericum perforatum (St. John’s Wort) after organ transplantation. Am J Kidney Dis 2001;38(5): 1105–1107.PubMedGoogle Scholar
  79. 79.
    Mandelbaum A, Pertzborn F, Martin-Facklam M, Wiesel M. Unexplained decrease of cyclosporine trough levels in a compliant renal transplant patient. Nephrol Dial Transplant 2000; 15:1473–1474.PubMedCrossRefGoogle Scholar
  80. 80.
    Karliova M, Treichel U, Malago M, Frilling A, Gerken G, Broelsch CE. Interaction of Hypericum perforatum (St. John’s wort) with cyclosporine A metabolism in a patient after liver transplantation. J Hepatol 2000;33:853–855.PubMedCrossRefGoogle Scholar
  81. 81.
    Mai I, Stornier E, Bauer S, Kruger H, Budde K, Roots I. Impact of St. John’s wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 2003;18(4):819–822.PubMedCrossRefGoogle Scholar
  82. 82.
    Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J. Interaction of St. John’ s wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol 2003;56(6):683–690.PubMedCrossRefGoogle Scholar
  83. 83.
    Gorski JC, Hamman MA, Wang Z, Vasavada N, Huang S, Hall SD. The Effect of St. John’s Wort on the efficacy of oral contraception. Clin Pharmacol Ther;71(2):P25.Google Scholar
  84. 84.
    Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St. John’s wort. Lancet 2000;355:547–549.PubMedCrossRefGoogle Scholar
  85. 85.
    de Maat MMR, Hoetelmans RMW, Mathot RAA, et al. Drug interactions between St. John’s wort and nevirapine. AIDS 2001;15(3):420–421.PubMedCrossRefGoogle Scholar
  86. 86.
    Rengelshausen J, Banfield M, Riedel KD, et al. Opposite effects of short-term and long-termSt. John’s wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther 2005;78(l):25–33.PubMedCrossRefGoogle Scholar
  87. 87.
    Smith PF, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ. The influence of St. John’s Wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 2004;24(11): 1508–1514.PubMedCrossRefGoogle Scholar
  88. 88.
    Crowe S, McKeating K. Delayed emergence and St. John’s Wort. J Am Soc Anesth 2002;9(4): 1025–1027.Google Scholar
  89. 89.
    Irefin S, Sprung J. A possible cause of cardiovascular collapse during anesthesia: long-term use of St. John’s Wort. J Clin Anesth 2000;12:498–499.PubMedCrossRefGoogle Scholar
  90. 90.
    Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66(4):338–345.PubMedCrossRefGoogle Scholar
  91. 91.
    Xie HG, Kim RB. St. John’s wort-associated drug interactions: short-term inhibition and long-term induction? Clin Pharmacol Ther 2005;78(l): 19–24.PubMedGoogle Scholar
  92. 92.
    Briggs GG, Freeman RK, Yaffe S J. Drugs in pregnancy and lactation. Briggs Update 1999;12(3): 17–19.Google Scholar
  93. 93.
    Klier CM, Schafer MR, Schmid-Siegel B, Lenz G, Mannel M. St. John’s Wort (Hypericum Perforatum)—Is it safe during breastfeeding? Pharmacopsychiatry 2002;35:29–30.PubMedCrossRefGoogle Scholar
  94. 94.
    Lee A, Minhas R, Ito S. Safety of St. John’s Wort during breastfeeding. Am Soc Clin Pharmacol Ther 2000; 130.Google Scholar
  95. 95.
    United States Pharmacopoeia (USP), ed. National Formulary, 18th edition, Supplement 9. Rockville: United States Pharmacopeial Convention, 1998.Google Scholar
  96. 96.
    Blumenthal M. St. John’s wort. The complete German Commission E monographs. Austin: American Botanical Council, 1998.Google Scholar

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  • Dean Filandrinos
  • Thomas R. Yentsch
  • Katie L. Meyers

There are no affiliations available

Personalised recommendations